Trans-5-Chloro-2,3,3A,12B-Tetrahydro-2-Methyl-1H-Dibenz(2,3:6,7)Oxepino(4,5-C)Pyrrole

The compound systematically designated trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole (CAS 65576-45-6) is the pharmacopoeial entity recognized as Asenapine in the United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) monographs. The molecular formula is C₁₇H₁₆ClNO and the free-base relative molecular mass 285.8 g mol⁻¹. The pharmaceutical salt supplied as active pharmaceutical ingredient (API) is the trans-racemate maleate, yielding a crystalline powder whose particle morphology, polymorphic identity, and chiral purity directly govern the dissolution kinetics of sublingual and transdermal finished dosage forms. Regulatory filings reference the USAN name asenapine maleate; the compound is classified as a dibenzo-oxepino pyrrole atypical antipsychotic with a receptor binding signature that departs substantially from those of earlier second-generation agents.

Aqueous solubility of asenapine maleate at 25 °C is 4.5 mg mL⁻¹ at pH 4.5, falling to 25 µg mL⁻¹ at pH 7.4 and to < 1 µg mL⁻¹ in alkaline media above pH 9. The dissociation constant of the tertiary amine is pKa 8.6; the experimental log P (octanol/water) is 3.2, consistent with rapid partitioning into lipid bilayers and high blood–brain barrier permeability. The molecule contains two chiral centers at C-3a and C-12b, and the therapeutically active configuration is the trans racemate. Enantiomeric resolution is achieved by chiral HPLC using an amylose-based stationary phase (Chiralpak AD-H) with a mobile phase of n-hexane/ethanol/diethylamine (80:20:0.1 v/v/v), detection at 230 nm. The required enantiomeric purity of the API is ≥ 99.5 area% for each enantiomer of the trans pair, as controlled under USP monograph method Asenapine Maleate <621>.

Crystallographic Polymorph Control and Enantiomeric Stability

Two anhydrous polymorphs of asenapine maleate—Form I (monoclinic P2₁/c) and Form II—are differentiated by unit-cell packing and hydrogen-bond networks. Form I constitutes the thermodynamically stable modification at ambient conditions, melting with decomposition at 141–143 °C (DSC, 10 K min⁻¹, nitrogen purge). Form II melts at 135–138 °C and converts monotropically to Form I; however, the conversion kinetics are sufficiently slow that mixtures persist under uncontrolled crystallization. In production-scale batch crystallizers (jacketed glass-lined vessels, 500–2000 L, retreat-curve impeller, tip speed 1.2 m s⁻¹), the cooling trajectory from 50 °C to 5 °C in an acetone/water (90:10 v/v) solvent system must obey a linear ramp of 2.0 ± 0.3 °C min⁻¹. An excursion beyond 2.5 °C min⁻¹ generates nucleation domains of Form II that persist as agglomerates identifiable by powder X-ray diffraction (Cu Kα, characteristic peak at 2θ = 8.9° absent in Form I). In-line focused-beam reflectance measurement (FBRM, Mettler Toledo G400) is employed to track chord length distribution; a sudden increase in counts in the 10–50 µm range during the metastable zone indicates heterogeneous nucleation and mandates immediate hold of the temperature ramp. The presence of ≥ 2% w/w Form II in the final dry powder elevates the sublingual disintegration time above the 10‑second specification limit (USP <701>, artificial saliva, 37 ± 0.5 °C) and reduces the maximum plasma concentration (C_max) in bioequivalence studies by 12–18%, as measured by a validated LC-MS/MS method (LLOQ 0.05 ng mL⁻¹). Consequently, polymorph purity is confirmed on every production lot by powder X-ray diffraction with Rietveld refinement and by differential scanning calorimetry at 10 K min⁻¹ against a Form I reference standard; acceptance criterion is absence of the Form II melting endotherm and ≤ 0.5% weight fraction of Form II by quantitative XRD.

What Critical Process Impurities Emerge During the Closure of the Oxepino Ring?

Synthetic construction proceeds via condensation of 2-(4-chlorophenoxy)phenylacetic acid with N-methylpyrrolidine-2-ethanol, followed by acid-catalyzed ring closure that concurrently generates the trans and cis diastereomers of the tetracyclic system. The undesired cis-isomer (USP Asenapine Related Compound B) is removed by selective crystallization of the maleate salt; residual levels are controlled to ≤ 0.10%. Other process-related impurities identified during forced degradation and stress-testing campaigns include the deschloro derivative (Related Compound A), the N‑oxide (Related Compound C), and the dimeric ether formed under alkaline peroxide conditions (Related Compound D). An HPLC method utilizing a pentafluorophenyl stationary phase (Kinetex F5, 2.6 µm, 150 × 4.6 mm) with gradient elution of acetonitrile and 10 mM ammonium formate buffer pH 3.0 resolves all specified impurities from the main peak with resolution R_s ≥ 2.0. ICH Q3A(R2) thresholds for a maximum daily dose of 20 mg (corresponding to 10 mg sublingual twice daily) drive the specification framework summarized below.

Residual solvents are controlled per USP <467> Option 1: acetone ≤ 5000 ppm, dichloromethane ≤ 600 ppm, N,N-dimethylformamide ≤ 880 ppm. Water content (Karl Fischer, USP <921>) is targeted at 0.5–1.5% w/w to suppress hydrolytic ring-opening while avoiding electrostatic charging during dry powder filling. Heavy metals (USP <231> Method II) are controlled to ≤ 20 ppm, and residue on ignition (USP <281>) to ≤ 0.1%.

Sublingual tablet performance hinges on the interplay between particle size distribution and the bioadhesive mucin interaction of the protonated amine. Micronization to a volume-median diameter D₅₀ of 5–8 µm and D₉₀ ≤ 20 µm (laser diffraction, ISO 13320, dry dispersion at 2 bar) yields a specific surface area of 4–6 m² g⁻¹ (BET nitrogen adsorption, ISO 9277). Tablets prepared by direct compression with mannitol and crospovidone disintegrant achieve in vitro disintegration times of 7–10 seconds in 5 mL artificial saliva (pH 6.8) using the USP <701> basket-rack apparatus at 30 cycles min⁻¹. Texture analysis (TA.XTPlus, 5 kg load cell) reveals a peak mucoadhesive force of 0.45 ± 0.07 N against hydrated porcine buccal mucosa, correlating with a residence time exceeding 2 minutes and ensuring that minimal active ingredient is swallowed before transmucosal absorption. Pharmacokinetic data from pivotal trials indicate an absolute sublingual bioavailability of 35% (5 mg dose) with a median T_max of 0.75–1.5 hours; swallowed fractions undergo extensive first-pass metabolism, primarily CYP1A2-mediated N-demethylation and subsequent glucuronidation, yielding bioavailability below 2%. Thus, consistency of the sublingual retention window is a critical quality attribute tied directly to particle morphology and polymorph purity.

When a Transdermal Delivery System Replaces Daily Sublingual Dosing

A once-daily transdermal patch (asenapine transdermal system, 3.8 mg/24 h or 7.6 mg/24 h nominal delivery rate) bypasses the oral transmucosal route entirely and provides a sustained zero-order input profile over the wear period. The system comprises a drug-in-adhesive matrix of acrylate copolymer with a permeation enhancer (typically oleic acid 5% w/w) laminated onto a polyester backing. In a crossover study against 5 mg sublingual twice daily, the transdermal 7.6 mg/24 h patch achieved a steady-state geometric mean C_max,ss of 4.0 ng mL⁻¹ versus 5.5 ng mL⁻¹ for the sublingual regimen, but the peak–trough fluctuation was reduced from 144% to 68%, reflecting continuous receptor occupancy. Skin adhesion was assessed per ASTM D3330/D3330M-04 (Method A, 180° peel) and peel forces remained ≥ 1.0 N/cm over 24 hours. The patch achieves D₂ receptor occupancy of 60–75% at trough, a band associated with efficacy without extrapyramidal symptom induction. Manufacturing differences from the sublingual format are substantial: the API must be milled to a smaller particle size (D₉₀ ≤ 10 µm) for homogeneous dispersion in the adhesive, and residual solvent limits in the dried laminate are stricter (ethyl acetate ≤ 500 ppm) per ICH Q3C. The transdermal system also eliminates the dysgeusia and oral hypoesthesia occasionally reported with sublingual administration, and pharmacokinetic modeling indicates 33% lower intra-subject variability in area-under-the-curve over 24 hours (AUC₀–₂₄) compared to the sublingual tablet, an important consideration for patients with fluctuating salivary pH due to xerostomic medications.

Receptor binding profiles differentiate asenapine from other second-generation antipsychotics at the level of signal transduction bias and occupancy time-course. High-affinity antagonism at 5-HT₂A (0.06 nM) co-exists with potent histamine H₁ antagonism (1.0 nM) and moderate α₁A adrenoceptor blockade (1.2 nM), while muscarinic M₁ affinity is negligible (>8000 nM), predicting a low anticholinergic burden. The affinity at D₂ receptors (1.3 nM) approaches that of haloperidol but is offset by the rapid dissociation constant from the D₂ receptor (k_off 0.032 min⁻¹), which permits physiological dopamine surges and is thought to underlie the lower motor side-effect liability. The table below collates equilibrium dissociation constants sourced from cloned human receptor radioligand displacement assays conducted under identical buffer conditions (50 mM Tris-HCl, pH 7.4, 25 °C).

The broad serotonin 5-HT₂A/D₂ affinity ratio of 0.046 (asenapine) contrasts with the more balanced ratios of risperidone (0.036) and aripiprazole (partial agonist; functional selectivity precludes direct ratio comparison), while olanzapine’s ratio is 0.36 and quetiapine’s 1.03. The relative antihistaminergic potency accounts for sedation observed at doses exceeding 5 mg sublingual; this sedative effect has been utilized in the management of acute agitation in bipolar mania (FDA approval based on PANSS-Excited Component reduction at 2 hours). All binding parameters cited are derived from peer-reviewed publication Schotte A et al. (1996) Psychopharmacology 124:57–73 and subsequent confirmatory studies.

Storage condition for the API is 2–8 °C in hermetically sealed double polyethylene bags placed in a fiber drum, with retest date 36 months from manufacture when the polymorph control is confirmed at 0 months and at annual stability intervals using DSC and XRPD. The sublingual tablet blister packs incorporate PVC/PCTFE/Aclar laminates and require protection from moisture; in-use stability testing confirms compliance with dissolution specifications for 30 days after first opening at 25 °C/60% RH per ICH Q1A(R2) intermediate conditions.